Glucagon-like peptide-1 (GLP-1) analogs, widely used in type 2 diabetes mellitus (T2DM), have shown reduced risks of cardiovascular events, stroke, thrombotic events and all-cause mortality in populations with diabetes and obesity in previous studies [1, 2]. Here, GLP1R is linked to obesity disorder.